

Ref. No: FOI1755  
Date: 15/05/2025  
Subject: MS (Multiple Sclerosis) Diagnosis

## REQUEST & RESPONSE

1. How many patients has your trust treated in the past six months (for any disease) with the following drugs:

<b>Drug Name</b>	<b>Patient Number</b>
Aubagio (teriflunomide)	0
Avonex (interferon beta-1a)	0
Betaferon (interferon beta-1b)	0
Brabio (glatiramer acetate)	0
Copaxone (glatiramer acetate)	0
Extavia (beta interferon-1b)	0
Gilenya (fingolimod)	0
Kesimpta (ofatumumab)	0
Lemtrada (alemtuzumab)	0
Mavenclad (cladribine)	0
Mayzent (siponimod)	0
Ocrevus (ocrelizumab)	0
Plegridy (peginterferon beta-1a)	0
Ponvory (ponesimod)	0
Rebif (beta interferon-1a)	0
Tecfidera (dimethyl fumarate)	<5
Tysabri (natalizumab)	0
Tysabri (natalizumab) Pre-filled syringes only	0
Vumerity (diroximel fumarate)	0
Zeposia (ozanimod)	>5
Fingolimod generic	0
Tyruko (Natalizumab Biosimilar)	0

2. How many patients has you trust treated with Rituximab for MS (Multiple Sclerosis) in the past six months?

0

3. How many patients within your trust have a diagnosis of MS (Multiple Sclerosis)?

17 patients with a primary diagnosis of MS between 01/04/2024 and 30/04/2025